It is our pleasure to announce that Mike Watson has joined the Avance Clinical team as Director Business Development, USA.
Based in Raleigh North Carolina, Mike is a seasoned business development professional having spent the past 12 years in the clinical research space.
The leading Australian CRO for biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical, joins Medrio’s new podcast series Trial Talks. Trial Talks season 1, episode 1 “Why Clinical Trials are Thriving in Australia” focuses on how Avance Clinical prepared for the pandemic, what tools were leveraged that allowed trial continuation, and why clinical trials are currently thriving in the region.
The leading Australian CRO for biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical has been contracted to conduct a clinical study of Atossa Therapeutics’ proprietary drug candidate AT-301, to be administered by nasal spray. Avance has successfully completed multiple clinical studies of Atossa’s proprietary Endoxifen.
The leading Australian CRO for biotechs, Avance Clinical, accepted the prestigious Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award at a global virtual awards ceremony overnight.
Webinars CLICK HERE to Register for our Webinar Series on conducting clinical trials in Australia. Next: Early Phase Clinical Trials: Why taking the whole-of-health perspective is critical Date: 05th Aug 2020 Time: 01:30 PM (Singapore Time) We partner with leading biotech media companies such as Biospectrum Asia to share the latest on Australian clinical trials. Podcasts CLICK HERE to […]
Adelaide, Australia – The leading Australian CRO for biotechs, Avance Clinical announced at BIO Digital today that Australia currently has 2,413 trials planned or ongoing.
Importantly in Australia, despite the global COVID-19 pandemic, no healthy volunteer studies have been suspended, and only 27 Phase 1 or 2 studies were temporarily put on hold for various reasons (TrialTrove, 9 June 2020).
The leading Australian CRO for biotechs, Avance Clinical, hosted a visit with the Premier of South Australia the Hon. Steven Marshall MP to discuss the fast-growing clinical trials sector, currently worth $50 billion and increasing to $71.7 billion by 2024 according to Frost & Sullivan.
As oncology sponsors look internationally to speed-up trials after unprecedented COVID-19 suspensions and delays, Australia, which has led the world in minimizing the pandemic’s impact, stands out as an attractive destination for early phase trials. This in combination with the streamlined regulatory system and the financial benefits including a very favourable exchange rate and the R & D cash rebate makes Australia the perfect location for accelerating biotech clinical programs.
A joint BiospectrumAsia and Avance Clinical special webinar featuring Gabriel KremmidiotisPhD, BSC Hon, Chief Scientific Officer Avance Clinical. Registration is now open CLICK HERE
Avance Clinical, which has been offering CRO services for more than two decades for early phase trials, reports 95 new trials were registered in the past 30 days as recorded in Australian and New Zealand registry ANZCTR.org.au Read the news article here